Drugs / JAB-BX102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05174585 | Aug 2022 → May 2025 | cancer | Jacobio Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JAB-BX102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05174585 ↗ |
| Action | Inhibit | “anti-CD73 monoclonal antibody” NCT05174585 ↗ |
| Modality | Monoclonal antibody | “anti-CD73 monoclonal antibody” NCT05174585 ↗ |
| Route | Intravenous | “Administered by intravenous infusion (IV)” NCT05174585 ↗ |